Implantation Of Vaginal Construct For Patients With Vaginal Aplasia

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexFemale
Age15-45
SponsorWake Forest University Health Sciences

About this trial

In this Phase 1, single site, clinical trial, Vulvar/vaginal Smooth muscle cells (SMC) and Epithelial Cells (EPC) are isolated from autologous patient's biopsy

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosed with congenital Mullerian duct anomaly that includes absence or obliteration of all or part of the vagina, as confirmed on pelvic MRI

Females between the ages of 15 and 45 years

Patients with stable medical comorbidities

Patients that are willing to comply with all study instructions and are willing to return for study follow-up visits

Disqualifiers

Patients with a history of surgery in the target area more recent than the last 6 months

Patients with an active vaginal area infection or urinary infection as evidenced by clinical exam or culture result

Patients with a history of keloid scarring

Patients who are currently taking anti-platelet medications or blood thinners

Trial design

Design model

Single group

Treatments tested in this trial

  • biologic vaginal-construct implantation

    Biological/Vaccine

    biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: autologous vaginal construct for patients with vaginal aplasiaExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Number of Serious Adverse Events

bleeding, pain, visceral injury, vaginal scarring, contraction, or infection

Time frame
Month 36
2

Quality of Life Scores

The Quality of Life Scores (QOLS) is scored by adding up the score on each item to yield a total score for the instrument. Scores can range from 16 to 112 - the higher score indicates the higher quality of life

Time frame
Baseline
3

Quality of Life Scores

The Quality of Life Scores (QOLS) is scored by adding up the score on each item to yield a total score for the instrument. Scores can range from 16 to 112 - the higher score indicates the higher quality of life

Time frame
Month 36

Secondary outcomes

1

Change in Quality of life Female Sexual Function Index (FSFI) Scores

The Female Sexual Function Index (FSFI) is a multidimensional measure of female sexual functioning with 19 items that have ordinal, Likert- type response formats and are scored from 0 (or 1) to 5. The scoring algorithm sums items on each domain/sub-scale and then scales the sums so that each subscale has a maximum score of 6 - The FSFI is a survey measuring the sexual functioning of women in six different domains: desire, arousal, lubrication, orgasm, satisfaction and pain - Higher scores indicate better functioning

Time frame
Month 3, Month 6, Month 12, and Month 36

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.